{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:30:06Z","timestamp":1762867806185,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017077","name":"Hospira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ekir.2019.05.010","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:09:01Z","timestamp":1558483741000},"page":"1235-1247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney\u00a0Disease"],"prefix":"10.1016","volume":"4","author":[{"given":"Steven","family":"Fishbane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce S.","family":"Spinowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne A.","family":"Wisemandle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2019.05.010_bib1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1681\/ASN.V1271501","article-title":"Management of patients with chronic renal insufficiency in the Northeastern United States","volume":"12","author":"Kausz","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.05.010_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/ajkd.2001.27699","article-title":"Anemia: an early complication of chronic renal insufficiency","volume":"38","author":"Kazmi","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.05.010_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5507\/bp.2013.093","article-title":"Pathophysiology of anemia in chronic kidney diseases: a review","volume":"159","author":"Zadrazil","year":"2015","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"author":"Janssen Products","key":"10.1016\/j.ekir.2019.05.010_bib5"},{"key":"10.1016\/j.ekir.2019.05.010_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.05.010_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJM198907203210305","article-title":"Treatment of the anemia of progressive renal failure with recombinant human erythropoietin","volume":"321","author":"Eschbach","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.05.010_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/00041552-199212000-00005","article-title":"Treatment of renal anemia with recombinant human erythropoietin","volume":"1","author":"Macdougall","year":"1992","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2019.05.010_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.ajkd.2014.11.018","article-title":"The emerging role of biosimilar epoetins in nephrology in the United States","volume":"65","author":"Fishbane","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.05.010_bib21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.2215\/CJN.11631017","article-title":"Intravenous epoetin alfa-epbx versus epoetin alfa for treatment of anemia in end-stage kidney disease","volume":"13","author":"Fishbane","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.05.010_bib22","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins","volume":"106","author":"Hamuro","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.ekir.2019.05.010_bib24","first-page":"1298473","article-title":"Immunogenicity of biotherapeutics: causes and association with posttranslational modifications","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.ekir.2019.05.010_bib25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0272-6386(95)90654-1","article-title":"Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients","volume":"26","author":"Paganini","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.05.010_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12325-010-0012-y","article-title":"Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia","volume":"27","author":"Krivoshiev","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2019.05.010_bib29","unstructured":"Medical Dictionary of Regulatory Activities, version 14.1. 2011. Available at: https:\/\/www.meddra.org\/. Accessed 24 June 2019."},{"key":"10.1016\/j.ekir.2019.05.010_bib30","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1185\/030079908X297402","article-title":"Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia","volume":"24","author":"Krivoshiev","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2019.05.010_bib31","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1046\/j.1523-1755.2003.00229.x","article-title":"Hemoglobin variability in epoetin-treated hemodialysis patients","volume":"64","author":"Berns","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.05.010_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/ajkd.2003.50030","article-title":"Effect of variability in anemia management on hemoglobin outcomes in ESRD","volume":"41","author":"Lacson","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.05.010_bib33","first-page":"195","article-title":"Erythropoietin stimulating agents in the management of anemia of chronic kidney disease","volume":"2","author":"Hayat","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ekir.2019.05.010_bib34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000441-200603000-00007","article-title":"Increased mortality in chronic kidney disease: a call to action","volume":"331","author":"Perazella","year":"2006","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ekir.2019.05.010_bib35","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.05.010_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/157488610792245993","article-title":"Immunogenicity and its impact on benefit\/risk considerations in the authorisation of biopharmaceuticals","volume":"5","author":"Buttel","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.ekir.2019.05.010_bib38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/ki.2011.500","article-title":"Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights","volume":"81","author":"Macdougall","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.05.010_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K","article-title":"Human immune response to recombinant human proteins","volume":"90","author":"Porter","year":"2001","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.ekir.2019.05.010_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00185868.2016.1175203","article-title":"Renal dialysis and its financing","volume":"94","author":"Borelli","year":"2016","journal-title":"Hosp Top"},{"key":"10.1016\/j.ekir.2019.05.010_bib42","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2215\/CJN.03830414","article-title":"Rebasing the Medicare payment for dialysis: rationale, challenges, and opportunities","volume":"9","author":"Wish","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919302050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919302050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:25:25Z","timestamp":1762831525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024919302050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2468024919302050"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2019.05.010","relation":{},"ISSN":["2468-0249"],"issn-type":[{"type":"print","value":"2468-0249"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney\u00a0Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2019.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}